Lipid-reduction variability and antidrug-antibody formation with bococizumab

Cited by (369)

Items 101–200 of 369

1. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study
   Fred McCush, Ellen Wang, Carla Yunis, Pamela F. Schwartz, Daniel J. Baltrukonis · 2023 · The AAPS Journal
2. Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment
   Yi Wen, Suntara Cahya, Wei Zeng, Joanne Lin, Xiaoli Wang, Ling Liu, Laurent P. Malherbe, Robert W. Siegel, Andrea Ferrante, Arunan Kaliyaperumal · 2020 · The AAPS Journal
3. Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
   Jing Li, Heyue Du, Yang Wang, Bert Aertgeerts, Gordon Henry Guyatt, Qiukui Hao, Yanjiao Shen, Ling Li, Na Su, Nicolas Delvaux et al. · 2022 · Heart
4. Novel lipid modifying drugs to lower LDL cholesterol
   Arjen J. Cupido, Laurens F. Reeskamp, John J.P. Kastelein · 2017 · Current Opinion in Lipidology
5. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem
   Michael Ulitzka, Stefania C. Carrara, Julius Grzeschik, Henri Kornmann, Björn M Hock, Harald Kolmar · 2020 · Protein Engineering Design and Selection
6. Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
   Alberto Corsini, Henry N. Ginsberg, M. John Chapman · 2025 · Pharmacology & Therapeutics
7. Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
   Joanna Grudzinska‐Goebel, Karin Benstein, Karien Bloem, Kyra J. Cowan, Boris Gorovits, Maria Jadhav, Melody Janssen, Vibha Jawa, Andrea Kießling, Daniel Kramer et al. · 2025 · Frontiers in Immunology
8. The immune functions of PCSK9: Local and systemic perspectives
   Xing Liu, Rong Suo, Calista Zhuo Yi Chan, Tong Liu, Gary Tse, Guangping Li · 2019 · Journal of Cellular Physiology
9. Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
   Folkert H. van Bruggen, G. B. J. Nijhuis, Sytse Ulbe Zuidema, Hendrika J. Luijendijk · 2020 · Expert Review of Clinical Pharmacology
10. PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease
    Michael M. Page, Gerald Francis Watts · 2017 · Diabetes Obesity and Metabolism
11. Recent Advances in Developing PCSK9 Inhibitors for lipid-lowering Therapy
    Antonio Lavecchia, Carmen Cerchia · 2019 · Future Medicinal Chemistry
12. Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018
    Tingting Li, Sida Jiang, Bingwei Ni, Qiuji Cui, Liu Qinan, Hongping Zhao · 2019 · International Journal of Molecular Sciences
13. Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies
    Wen‐Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui T. Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess et al. · 2024 · mAbs
14. Bococizumab for the treatment of hypercholesterolaemia
    Nicola Ferri, Alberto Corsini, Cesare Riccardo Sirtori, Massimiliano Ruscica · 2017 · Expert Opinion on Biological Therapy
15. Prediction of immunogenicity for humanized and full human therapeutic antibodies
    Shide Liang, Chi Zhang · 2020 · PLoS ONE
16. Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development
    Jochem Gokemeijer, Yi Wen, Vibha Jawa, Shibani Mitra‐Kaushik, Shan Chung, Alan Goggins, Seema Kumar, Kasper Lamberth, Karen Liao, Jennie Rebecca Lill et al. · 2023 · The AAPS Journal
17. Efficacy and safety of PCSK9 monoclonal antibodies
    Zohaib Iqbal, Shaishav Shashikant Dhage, Jamal Basheer Mohamad, A.E.S. Abdel-Razik, Rachelle P. Donn, Rayaz Ahmed Malik, Jan Hoong Ho, Yifen Liu, Safwaan Adam, Basil Isa et al. · 2019 · Expert Opinion on Drug Safety
18. Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
    Jah Yeon Choi, Jin Oh Na · 2019 · Journal of Lipid and Atherosclerosis
19. Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
    Maria Cristina de Oliveira Izar, Viviane Zorzanelli Rocha, Adriana Bertolami, Raul Dias Santos, Ana Maria Lottenberg, Marcelo Heitor Vieira Assad, José Francisco Kerr Saraiva, Ana Paula Marte Chacra, Tânia Leme da Rocha Martinez, Luciana Bahia et al. · 2021 · Arquivos Brasileiros de Cardiologia
20. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
    Qiang Geng, Xuan Li, Qingjiao Sun, Zhengzhong Wang · 2021 · Cardiology Journal
21. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials
    Jie Bai, Lilin Gong, Qifu Li, Zhihong Wang · 2018 · Journal of clinical lipidology
22. Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis
    Jeanne M. Dobrzynski, John B. Kostis, Davit Sargsyan, Stavros Zinonos, William J. Kostis · 2018 · Journal of clinical lipidology
23. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
    Eun Ji Kim, Anthony S. Wierzbicki · 2020 · Therapeutic Advances in Chronic Disease
24. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy
    Chayakrit Krittanawong, Muzamil Khawaja, Robert S. Rosenson, Christopher Ian Amos, Vijay Nambi, Carl J. Lavie, Salim S. Virani · 2021 · Current Problems in Cardiology
25. Investigation of Immune Responses to Oxidation, Deamidation, And Isomerization in Therapeutic Antibodies using Preclinical Immunogenicity Risk Assessment Assays
    Rachel Zeunik, Aya F. Ryuzoji, Amber Peariso, Xiaoli Wang, Megan B. Lannan, Laura J. Spindler, Michael D. Knierman, Victoria Copeland, Chetan N. Patel, Yi Wen · 2022 · Journal of Pharmaceutical Sciences
26. PCSK9-directed therapies: an update
    Katzmann, Julius L., Laufs, Ulrich · 2024 · Current Opinion in Lipidology
27. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
    Niki Katsiki, Vasilios Gabriel Athyros, Dimitri P. Mikhailidis, Christos Socrates Mantzoros · 2017 · Metabolism
28. The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia
    Roshni S. Patel, Emily M. Scopelliti, Oludamilola Olugbile · 2018 · Annals of Pharmacotherapy
29. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Qiwen Chen, Guodong Wu, Chuang Li, Xueting Qin, Rui Liu, Mei Zhang · 2019 · American Journal of Cardiovascular Drugs
30. Development of a Novel, Fully Human, Anti-PCSK9 Antibody with Potent Hypolipidemic Activity by Utilizing Phage Display-Based Strategy
    Menglong Xu, Gaoxin Lei, Manman Chen, Ke Wang, Wenxiu Lv, Panpan Zhang, Tuo Hu, Jie Gao, Chenchen Lü, Ying Mei et al. · 2020 · EBioMedicine
31. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort
    Alexander Dressel, Burkhard Schmidt, Nina Schmidt, Ulrich Laufs, Felix Fath, M. John Chapman, Tanja B. Grammer, Winfried März · 2019 · Vascular Pharmacology
32. Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients
    Seth G. Thacker, Cheng Her, Logan Kelley-Baker, Derek D.C. Ireland, Mohanraj Manangeeswaran, Eric S. Pang, Daniela I. Verthelyi · 2022 · Frontiers in Immunology
33. A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
    Louise Goksøyr, Magdalena Skrzypczak, Maureen L. Sampson, Morten Agertoug Nielsen, Ali Salanti, Thor Grundtvig Theander, Alan Thomas Remaley, Willem Adriaan de Jongh, Adam Frederik Sander · 2022 · Vaccines
34. New approaches to address dyslipidemia
    Klaus Georg Parhofer · 2017 · Current Opinion in Lipidology
35. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
    Gearoid Fitzgerald, T Kiernan · 2018 · Expert Review of Cardiovascular Therapy
36. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity
    Osman Nuri Yogurtcu, Zuben E. Sauna, Joseph R. McGill, Million A. Tegenge, Hong Yang · 2019 · The AAPS Journal
37. Anti-drug antibodies in the current management of cancer
    Miguel Borregón, Katherine Martínez, Alba Ramos, Irene Ramos, Beatriz Berzal, Manuel Mazariegos, Elia Martínez, Tatiana Hernández, Bernard Doger, Víctor Moreno · 2022 · Cancer Chemotherapy and Pharmacology
38. New Biological Therapies for Low-Density Lipoprotein Cholesterol
    Praneet K. Gill, Robert Alexander Hegele · 2023 · Canadian Journal of Cardiology
39. Present and Future of Dyslipidaemia Treatment—A Review
    Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Barbić Radman, Ivan Pećin, Željko Reiner · 2023 · Journal of Clinical Medicine
40. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
    Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata · 2017 · Vascular Health and Risk Management
41. Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
    Thanaputt Chaiyasothi, Surakit Nathisuwan, Piyameth Dilokthornsakul, Prin Vathesatogkit, Ammarin Thakkinstian, Christopher Michael Reid, Wanwarang Wongcharoen, Nathorn Chaiyakunapruk · 2019 · Frontiers in Pharmacology
42. The effects of single‐ and multiple‐dose administration of bococizumab ( RN 316/ PF ‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies
    Barry Gumbiner, Tenshang Joh, Liang Hong, Hong I. Wan, Matteo G. Levisetti, Alicia M. Vana, David L. Shelton, Philippe Forgues, Stephane Billotte, Jaume Pons et al. · 2017 · Cardiovascular Therapeutics
43. Maximizing the benefits of cholesterol-lowering drugs
    Kenneth R. Feingold · 2019 · Current Opinion in Lipidology
44. Fit-for-Purpose Validation and Establishment of Assay Acceptance and Reporting Criteria of Dendritic Cell Activation Assay Contributing to the Assessment of Immunogenicity Risk
    Dilki C. Wickramarachchi, Gregory S. Steeno, Zhiping You, S. Farzana Shaik, Christopher S. Lepsy, Xue Li · 2020 · The AAPS Journal
45. Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
    Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Binge Yu, Guoqin Wang, Fang Xu, Dongmei Lu, Zhimei He et al. · 2024 · Pharmacological Research
46. Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions
    Austin L. Daniels, Theodore W. Randolph · 2018 · Journal of Pharmaceutical Sciences
47. Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
    Stefan Weisshaar, Markus Alexander Zeitlinger · 2018 · Drugs
48. PCSK9 Inhibition to Reduce Cardiovascular Risk
    David D. Waters, Priscilla Y. Hsue · 2017 · Circulation Research
49. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive ― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ―
    Koutaro Yokote, Shigeto Kanada, Osamu Matsuoka, Hisakuni Sekino, Keiji Imai, Junichi Tabira, Nobushige Matsuoka, Sandip Chaudhuri, Tamio Teramoto · 2017 · Circulation Journal
50. PCSK9 in T-cell function and the immune response
    Yuying Wang, Xiaosheng Fang, Jiarui Liu, Xiao Lv, Kang Lu, Yingxue Lu, Yujie Jiang · 2024 · Biomarker Research
51. Novel treatment options for the management of heterozygous familial hypercholesterolemia
    Georgios Polychronopoulos, Κωνσταντίνος Τζιόμαλος · 2017 · Expert Review of Clinical Pharmacology
52. New Targets in Atherosclerosis: Vascular Smooth Muscle Cell Plasticity and Macrophage Polarity
    Michael Hutton, Madeleine Frazer, Alexander Lin, Sanjay Patel, Ashish Misra · 2023 · Clinical Therapeutics
53. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development
    M. Violet Lee, Ola M. Saad, Sylvia C. Wong, Jason Lamar, Lynn A. Kamen, Benjamin Ordonia, Rachel Melendez, Azadeh Hassanzadeh, Shan Chung, Surinder Kaur · 2023 · Frontiers in Immunology
54. A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics
    Nicole L. Jarvi, Sathy V. Balu‐Iyer · 2023 · Communications Medicine
55. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin
    Sergio Fazio, David G. C. Robertson, Tenshang Joh, Hong I. Wan, Tom Riel, Philippe Forgues, Charles M. Baum, Pamela D. Garzone, Barry Gumbiner · 2017 · Cardiovascular Therapeutics
56. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis
    Alessandro Squizzato, Matteo Basilio Suter, Marta Nerone, Robert Patrick Giugliano, Francesco Dentali, Andrea Maria Maresca, Leonardo Campiotti, Anna Maria Grandi, Luigina Guasti · 2017 · Internal and Emergency Medicine
57. Optimizing PCSK9 inhibitor therapy: Understanding and managing suboptimal LDL-C response in clinical practice
    Filippo Giorgio Di Girolamo, Lisa Pellin, Chiara Roni, Gianni Biolo, Gianfranco Sinagra, Enrico Fabris · 2025 · European Journal of Internal Medicine
58. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors
    Rita Del Pinto, Davide Grassi, Giuliana Properzi, Giovambattista Desideri, Claudio Ferri · 2019 · High Blood Pressure & Cardiovascular Prevention
59. PCSK9 monoclonal antibodies: An overview
    Rasha Kaddoura, Bassant Orabi, Amar Mohammad Salam · 2020 · Heart Views
60. Pharmacokinetics of current and emerging treatments for hypercholesterolemia
    Brian Tomlinson, Paul Chan, Yuzhen Zhang, Zhongmin Liu, Christopher Wai Kei Lam · 2020 · Expert Opinion on Drug Metabolism & Toxicology
61. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
    Kyung Hoon Cho, Young Joon Hong · 2020 · The Korean Journal of Internal Medicine
62. Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia
    Raul Dias Santos · 2018 · Arteriosclerosis Thrombosis and Vascular Biology
63. The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment
    Testa, Gabriella, Giannelli, Serena, Staurenghi, Erica, Cecci, Rebecca, Floro, Lucrezia, Gamba, Paola, Sottero, Barbara, Leonarduzzi, Gabriella · 2024 · International Journal of Molecular Sciences
64. Selection of biophysically favorable antibody variants using a modified Flp-In CHO mammalian display platform
    Olli Huhtinen, Rune Salbo, Urpo Lamminmäki, Stuart Prince · 2023 · Frontiers in Bioengineering and Biotechnology
65. Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance
    Nicola Ferri, Elisa Colombo, Alberto Corsini · 2024 · Hematology Reports
66. Triglyceride-lowering trials
    ANTHONY C. KEECH, Alicia Josephine Jenkins · 2017 · Current Opinion in Lipidology
67. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
    Giovanni Ciccarelli, Saverio D’Elia, Michele De Paulis, Paolo Golino, Giovanni Cimmino · 2018 · Diseases
68. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
    Gregory S. Pokrywka · 2018 · Postgraduate Medicine
69. SampPick: Selection of a Cohort of Subjects Matching a Population HLA Distribution
    Joseph R. McGill, Osman Nuri Yogurtcu, Daniela I. Verthelyi, Hong Yang, Zuben E. Sauna · 2019 · Frontiers in Immunology
70. Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
    Mingqi Ouyang, Chenyu Li, Die Hu, Daoquan Peng, Bilian Yu · 2022 · Clinica Chimica Acta
71. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Dimitrios Delialis, Maria‐Angeliki Dimopoulou, Maria Papaioannou, Georgia Kotsira, Eleni Maneta, Georgios Mavraganis, Christos Loutos, Georgios A. Georgiopoulos, Kimon S. Stamatelopoulos · 2023 · Current Pharmaceutical Design
72. Third generation PCSK9-inhibitors
    Ulrich Laufs, Matthias Blüher, Berend Isermann · 2023 · European Heart Journal
73. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis
    Bayan Moustafa, Daniel Oparowski, Sofia Testai, Ilan Guman, Gabriela Trifan · 2024 · Journal of Stroke and Cerebrovascular Diseases
74. Challenging the Standard Immunogenicity Assessment Approach: 1-Tiered ADA Testing Strategy in Clinical Trials
    Ching‐Ha Lai, Mu Chen, Sasha Fraser, Jessica C Wang, Sean McAfee, Emma Speaks, Nicholas Simeone, Jacqueline Rodriguez, Colin Stefan, Lisa DeStefano et al. · 2024 · The AAPS Journal
75. Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model
    Hitoshi Maeda, Yuki Minayoshi, Shota Ichimizu, Yuki Mizuta, Taisei Nagasaki, Kotaro Matsusaka, Shun Oshiro, Kentaro Oniki, Junji Saruwatari, Yu Ishima et al. · 2019 · Biological and Pharmaceutical Bulletin
76. Comparability study of monocyte derived dendritic cells, primary monocytes, and THP1 cells for innate immune responses
    Yi Wen, Xiaoli Wang, Suntara Cahya, Paul Anderson, Candyd Velasquez, Carina Torres, Andrea Ferrante, Arunan Kaliyaperumal · 2021 · Journal of Immunological Methods
77. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK 9, after single subcutaneous injection at three sites [ NCT 02043301]
    Ellen Q. Wang, Anna Plotka, Joanne Salageanu, Catherine Sattler, Carla Yunis · 2017 · Cardiovascular Therapeutics
78. Biologics and Cardiovascular Disease
    John Van Taunay, Ma Teresa Albelda, Juan Carlos Frias, Michael Joseph Lipinski · 2018 · Journal of Cardiovascular Pharmacology
79. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function
    Patchareeya Amput, Christian McSweeney, Siripong Palee, Arintaya Phrommintikul, Siriporn Chaisin Chattipakorn, Nipon Chattipakorn · 2018 · Biomedicine & Pharmacotherapy
80. Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
    Alexandrina Danilov, William H. Frishman, Wilbert S. Aronow · 2022 · Cardiology in Review
81. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects
    Hong I. Wan, Barry Gumbiner, Tenshang Joh, Tom Riel, Chandrasekhar Udata, Philippe Forgues, Pamela D. Garzone · 2017 · Clinical Therapeutics
82. Proprotein convertase subtilisin/kexin type 9
    Robert M. Stoekenbroek, John J.P. Kastelein · 2018 · Current Opinion in Cardiology
83. Product-Related Factors and Immunogenicity of Biotherapeutics
    Murli Krishna · 2019 · Journal of Pharmaceutical Innovation
84. Cask methylation involved in the injury of insulin secretion function caused by interleukin1‐β
    Tianyuan Wang, Xingjing Liu, Jinyang Xie, Qingzhao Yuan, Yao Wang · 2020 · Journal of Cellular and Molecular Medicine
85. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
    Amir Abbas Momtazi‐Borojeni, Matteo Pirro, Suowen Xu, Amirhossein Sahebkar · 2021 · Current Medicinal Chemistry
86. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
    Bushra Hassan Marouf, Zohaib Iqbal, Jamal Basheer Mohamad, Bilal Bashir, Jonathan D. Schofield, Akheel A. Syed, Eric S Kilpatrick, Claudia Stefanutti, Handrean Soran · 2022 · Clinical Therapeutics
87. Emerging biologic therapies for hypercholesterolaemia
    Giacomo Pucci, Arrigo F.G. Cicero, Claudio Borghi, Giuseppe Schillaci · 2017 · Expert Opinion on Biological Therapy
88. Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
    Melody Hermel, Madison Lieberman, Leandro N. Slipczuk, Jamal S. Rana, Salim S. Virani · 2023 · Pharmaceutics
89. PCSK9 inhibition for LDL lowering and beyond – implications for patients with peripheral artery disease
    Katrin Gebauer, Holger Reinecke · 2018 · VASA
90. PCSK9: from molecular biology to clinical applications
    Jonathan Malo, Arun Parajuli, Simon W. Walker · 2019 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
91. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue
    Wojciech Jankowski, Joseph R. McGill, H. A. Daniel Lagassé, Stepan S. Surov, Gary P. Bembridge, Campbell Bunce, Edward A. Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Raheman Khan et al. · 2019 · Blood Advances
92. Assessment of Clinically Relevant Immunogenicity for mAbs; are we Over Reporting ADA?
    Mohamed Hassanein, Michael A. K. Partridge, Weiping Shao, Albert Torri · 2020 · Bioanalysis
93. Lipid Optimization in Lower Extremity Peripheral Arterial Disease
    Penelope Poppy Janpen Sucharitkul, Keely Louise Jones, David Julian Ashbridge Scott, Marc Aaron Bailey · 2021 · Annals of Vascular Surgery
94. Personalized Medicine in Lipid-Modifying Therapy
    Brian Tomlinson, Chen-Hsiu Lin, Paul Chan, Christopher Wai Kei Lam · 2021 · Personalized Medicine
95. Establishing endotoxin limits to enhance the reliability of in vitro immunogenicity risk assessments
    Yun Hee Jeong, Gillian Lennon, Geertruida M. Veldman, Daniel Serna, Alexander Ibrahimov · 2025 · mAbs
96. Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients
    Silvina Iluţ, Bianca O. Pîrlog, Radu Pîrlog, Andreea Mihaela Nutu, Vitalie Văcăraș, Sebastian Mihai Armean · 2022 · International Journal of Molecular Sciences
97. Status of PCSK9 Monoclonal Antibodies in Australia
    Daniel J Scherer, Adam J. Nelson, Richard Charles O’Brien, Karam Kostner, David L. Hare, David M. Colquhoun, Philip J. Barter, Philip E. Aylward, Stephen James Nicholls, Gerald Francis Watts · 2019 · Heart Lung and Circulation
98. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
    Ellen Q. Wang, Jack F. Bukowski, Carla Yunis, Charles L. Shear, Paul M. Ridker, Pamela F. Schwartz, Daniel J. Baltrukonis · 2019 · BioDrugs
99. Insights from ORION studies: focus on inclisiran safety
    Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata · 2020 · Cardiovascular Research
100. Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
     Liwen Li, Yujie Zhou, Chanjuan Deng, Jianlong Sheng, Daoquan Peng, Zhiyu Ling, Luya Wang, Cuilian Dai, Kai Huang, Qiufang Lian et al. · 2025 · Cardiovascular Research